Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management.
Liquid biopsy
NET
PRRT
SSTR-PET
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
06
01
2021
accepted:
05
04
2021
pubmed:
28
4
2021
medline:
21
10
2021
entrez:
27
4
2021
Statut:
ppublish
Résumé
The aim of this narrative review is to give an overview on current and emerging imaging methods and liquid biopsy for prediction and evaluation of response to PRRT. Current limitations and new perspectives, including artificial intelligence, are discussed. A literature review of PubMed/Medline was performed with representative keywords. The search included articles published online through August 31, 2020. All searches were restricted to English language manuscripts. Peptide radio receptor therapy (PRRT) is a prospectively evaluated and approved therapy option in neuroendocrine tumors (NETs). Different ligands targeting the somatostatin receptor (SSTR) are used as theranostic pairs for imaging NET and for PRRT. Response assessment in prospective trials often relies on the morphological RECIST 1.1 criteria, based on lesion size in CT or MRI. The role of SSTR-PET and quantitative uptake parameters and volumetric data is still not defined. Monoanalyte tumor marker chromogranin A has a limited value for response assessment after PRRT. New emerging liquid biopsy techniques are offering prediction of response to PRRT and prognostic value. New response criteria for NET patients undergoing PRRT will comprise multiparametric hybrid imaging and blood-based multianalyte markers. This represents tumor biology and heterogeneity.
Identifiants
pubmed: 33903926
doi: 10.1007/s00259-021-05359-3
pii: 10.1007/s00259-021-05359-3
pmc: PMC8484222
doi:
Substances chimiques
Receptors, Somatostatin
0
Octreotide
RWM8CCW8GP
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4016-4027Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42.
pubmed: 28448665
pmcid: 5824320
doi: 10.1001/jamaoncol.2017.0589
Clift AK, Kidd M, Bodei L, Toumpanakis C, Baum RP, Oberg K, et al. Neuroendocrine neoplasms of the small bowel and pancreas. Neuroendocrinology. 2020;110:444–76.
pubmed: 31557758
doi: 10.1159/000503721
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.
pubmed: 18565894
doi: 10.1200/JCO.2007.15.4377
Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez del Prado MP, Alonso Orduña V, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010;21:1794–803.
pubmed: 20139156
doi: 10.1093/annonc/mdq022
Malczewska A, Kos-Kudła B, Kidd M, Drozdov I, Bodei L, Matar S, et al. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors. Adv Med Sci. 2020;65:18–29.
pubmed: 31841822
doi: 10.1016/j.advms.2019.10.002
Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors. Cancer. 2008;113:5–21.
pubmed: 18473355
doi: 10.1002/cncr.23542
Boyar Cetinkaya R, Aagnes B, Thiis-Evensen E, Tretli S, Bergestuen DS, Hansen S. Trends in incidence of neuroendocrine neoplasms in Norway: a report of 16,075 cases from 1993 through 2010. Neuroendocrinology. 2017;104:1–10.
pubmed: 26562558
doi: 10.1159/000442207
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177 Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.
pubmed: 28076709
pmcid: 5895095
doi: 10.1056/NEJMoa1607427
Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, et al. NANETS/SNMMI procedure standard for somatostatin receptor–based peptide receptor radionuclide therapy with 177Lu-Dotatate. J Nucl Med. 2019;60:937–43.
pubmed: 31263080
doi: 10.2967/jnumed.118.230607
Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, et al. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J Nucl Med. 2018;59:66–74.
pubmed: 29025982
pmcid: 6910630
doi: 10.2967/jnumed.117.202275
Krenning EP, de Jong M, Kooij PPM, Breeman WAP, Bakker WH, de Herder WW, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10:S23–9.
pubmed: 10399029
doi: 10.1093/annonc/10.suppl_2.S23
Hofman MS, Eddie Lau WF, Hicks RJ. Somatostatin receptor imaging with68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35:500–16.
pubmed: 25763733
doi: 10.1148/rg.352140164
de Mestier L, Dromain C, d’Assignies G, Scoazec J-Y, Lassau N, Lebtahi R, et al. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocr Relat Cancer. 2014;21:R105–20.
pubmed: 24351682
doi: 10.1530/ERC-13-0365
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
pubmed: 19097774
doi: 10.1016/j.ejca.2008.10.026
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S–50S.
doi: 10.2967/jnumed.108.057307
pubmed: 19403881
Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Higuchi T, Weich A, et al. Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications. Ann Nucl Med. 2018;32:512–22.
pubmed: 30109562
pmcid: 6182628
doi: 10.1007/s12149-018-1291-7
Liberini V, Huellner MW, Grimaldi S, Finessi M, Thuillier P, Muni A, et al. The challenge of evaluating response to peptide receptor radionuclide therapy in gastroenteropancreatic neuroendocrine tumors: the present and the future. Diagnostics. 2020;10:1083.
pmcid: 7763988
doi: 10.3390/diagnostics10121083
Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, et al. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16:e435–46.
pubmed: 26370353
pmcid: 5023063
doi: 10.1016/S1470-2045(15)00186-2
Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, de Herder WW, Feelders RA, et al. Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [(177)Lu-DOTA(0), Tyr(3)]octreotate. Endocr Relat Cancer. 2017;24:243–51.
pubmed: 28320783
doi: 10.1530/ERC-16-0524
Malczewska A, Kidd M, Matar S, Kos-Kudla B, Modlin IM. A comprehensive assessment of the role of miRNAs as biomarkers in gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology. 2018;107:73–90.
pubmed: 29566385
doi: 10.1159/000487326
Hope TA, Calais J, Zhang L, Dieckmann W, Millo C. (111)In-pentetreotide scintigraphy versus (68)Ga-DOTATATE PET: impact on Krenning scores and effect of tumor burden. J Nucl Med. 2019;60:1266–9.
pubmed: 30850506
pmcid: 6735279
doi: 10.2967/jnumed.118.223016
Durante C, Boukheris H, Dromain C, Duvillard P, Leboulleux S, Elias D, et al. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer. 2009;16:585–97.
pubmed: 19240182
doi: 10.1677/ERC-08-0301
Pettersson O, Fröss-Baron K, Crona J, Sundin A. Tumor contrast-enhancement for monitoring of PRRT 177Lu-DOTATATE in pancreatic neuroendocrine tumor patients. Front Oncol. 2020;10:1–9.
doi: 10.3389/fonc.2020.00193
Ronot M, Clift AK, Baum RP, Singh A, Kulkarni HR, Frilling A, et al. Morphological and functional imaging for detecting and assessing the resectability of neuroendocrine liver metastases. Neuroendocrinology. 2018;106:74–88.
pubmed: 28728155
doi: 10.1159/000479293
Hayoz R, Vietti-Violi N, Duran R, Knebel JF, Ledoux JB, Dromain C. The combination of hepatobiliary phase with Gd-EOB-DTPA and DWI is highly accurate for the detection and characterization of liver metastases from neuroendocrine tumor. Eur Radiol. 2020;30:6593–602.
pubmed: 32601948
doi: 10.1007/s00330-020-06930-6
Perez-Lopez R, Mateo J, Mossop H, Blackledge MD, Collins DJ, Rata M, et al. Diffusion-weighted imaging as a treatment response biomarker for evaluating bone metastases in prostate cancer: a pilot study. Radiology. 2017;283:168–77.
pubmed: 27875103
doi: 10.1148/radiol.2016160646
Labeur TA, Runge JH, Klompenhouwer EG, Klümpen H-J, Takkenberg RB, van Delden OM. Diffusion-weighted imaging of hepatocellular carcinoma before and after transarterial chemoembolization: role in survival prediction and response evaluation. Abdom Radiol (New York). 2019;44:2740–50.
doi: 10.1007/s00261-019-02030-2
Kukuk GM, Mürtz P, Träber F, Meyer C, Ullrich J, Gieseke J, et al. Diffusion-weighted imaging with acquisition of three b-values for response evaluation of neuroendocrine liver metastases undergoing selective internal radiotherapy. Eur Radiol. 2014;24:267–76.
pubmed: 24081644
doi: 10.1007/s00330-013-3008-6
Weber M, Kessler L, Schaarschmidt B, Fendler WP, Lahner H, Antoch G, et al. Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient. BMC Cancer. 2020;20:1–12.
doi: 10.1186/s12885-020-06836-y
Weikert T, Maas OC, Haas T, Klarhöfer M, Bremerich J, Forrer F, et al. Early prediction of treatment response of neuroendocrine hepatic metastases after peptide receptor radionuclide therapy with (90)Y-DOTATOC using diffusion weighted and dynamic contrast-enhanced MRI. Contrast Media Mol Imaging. 2019;2019:1517208.
pubmed: 31787860
pmcid: 6877975
Kim JH, Joo I, Kim TY, Han SW, Kim YJ, Lee JM, et al. Diffusion-related mri parameters for assessing early treatment response of liver metastases to cytotoxic therapy in colorectal cancer. Am J Roentgenol. 2016;207:W26–32.
doi: 10.2214/AJR.15.15683
Montelius M, Spetz J, Jalnefjord O, Berger E, Nilsson O, Ljungberg M, et al. Identification of potential MR-derived biomarkers for tumor tissue response to (177)Lu-Octreotate therapy in an animal model of small intestine neuroendocrine tumor. Transl Oncol. 2018;11:193–204.
pubmed: 29331677
pmcid: 5772005
doi: 10.1016/j.tranon.2017.12.003
Huizing DMV, Aalbersberg EA, Versleijen MWJ, Tesselaar MET, Walraven I, Lahaye MJ, et al. Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy. Cancer Imaging. 2020;20:57.
Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1—update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–7.
pubmed: 27189322
pmcid: 5737828
doi: 10.1016/j.ejca.2016.03.081
Gerwing M, Herrmann K, Helfen A, Schliemann C, Berdel WE, Eisenblätter M, et al. The beginning of the end for conventional RECIST - novel therapies require novel imaging approaches. Nat Rev Clin Oncol. 2019;16:442–58.
pubmed: 30718844
doi: 10.1038/s41571-019-0169-5
Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.
pubmed: 17470865
doi: 10.1200/JCO.2006.07.3049
Luo Y, Chen J, Huang K, Lin Y, Chen M, Xu L, et al. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria? BMC Cancer. 2017;17:154.
pubmed: 28231773
pmcid: 5324282
doi: 10.1186/s12885-017-3150-7
Binderup T, Knigge U, Mellon Mogensen A, Palnaes Hansen C, Kjaer A. Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology. 2008;87:223–32.
pubmed: 18196892
doi: 10.1159/000113128
Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, et al. Sensitivity comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study. J Nucl Med. 2018;59:915–21.
pubmed: 29191855
doi: 10.2967/jnumed.117.199760
Öksüz MÖ, Winter L, Pfannenberg C, Reischl G, Müssig K, Bares R, et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC? Diagn Interv Imaging. 2014;95:289–300.
pubmed: 24034971
doi: 10.1016/j.diii.2013.07.006
Sharma R, Wang WM, Yusuf S, Evans J, Ramaswami R, Wernig F, et al. 68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours. Radiother Oncol. 2019;141:108–15.
pubmed: 31542317
doi: 10.1016/j.radonc.2019.09.003
Seifert R, Herrmann K, Kleesiek J, Schäfers M, Shah V, Xu Z, et al. Semiautomatically quantified tumor volume using 68Ga-PSMA-11 PET as a biomarker for survival in patients with advanced prostate cancer. J Nucl Med. 2020;61:1786–92.
pubmed: 32332147
doi: 10.2967/jnumed.120.242057
Toriihara A, Baratto L, Nobashi T, Park S, Hatami N, Davidzon G, et al. Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019;46:2244–51.
pubmed: 31350603
doi: 10.1007/s00259-019-04455-9
Werner RA, Ilhan H, Lehner S, Papp L, Zsótér N, Schatka I, et al. Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy. Mol Imaging Biol. 2019;21:582–90.
pubmed: 30014345
doi: 10.1007/s11307-018-1252-5
Werner RA, Lapa C, Ilhan H, Higuchi T, Buck AK, Lehner S, et al. Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity. Oncotarget. 2017;8:7039–49.
pubmed: 27705948
doi: 10.18632/oncotarget.12402
Graf J, Pape UF, Jann H, Denecke T, Arsenic R, Brenner W, et al. Prognostic significance of somatostatin receptor heterogeneity in progressive neuroendocrine tumor treated with Lu-177 DOTATOC or Lu-177 DOTATATE. Eur J Nucl Med Mol Imaging. 2020;47:881–94.
pubmed: 31414209
doi: 10.1007/s00259-019-04439-9
Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med. 2009;50:1427–34.
pubmed: 19690033
doi: 10.2967/jnumed.108.053421
Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. Eur J Nucl Med Mol Imaging. 2017;44:1588–601.
pubmed: 28547177
doi: 10.1007/s00259-017-3728-y
Haug AR, Auernhammer CJ, Wängler B, Schmidt GP, Uebleis C, Göke B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51:1349–56.
pubmed: 20720050
doi: 10.2967/jnumed.110.075002
Abdulrezzak U, Kurt YK, Kula M, Tutus A. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors. Nucl Med Commun. 2016;37:874–81.
pubmed: 27096719
doi: 10.1097/MNM.0000000000000522
Roll W, Müther M, Sporns PB, Zinnhardt B, Suero Molina E, Seifert R, et al. Somatostatin receptor–targeted radioligand therapy in head and neck paraganglioma. World Neurosurg. 2020;143:e391–9.
pubmed: 32745642
doi: 10.1016/j.wneu.2020.07.165
Severi S, Nanni O, Bodei L, Sansovini M, Ianniello A, Nicoletti S, et al. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:881–8.
pubmed: 23443937
doi: 10.1007/s00259-013-2369-z
Ezziddin S, Adler L, Sabet A, Pöppel TD, Grabellus F, Yüce A, et al. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system. J Nucl Med. 2014;55:1260–6.
pubmed: 24876204
doi: 10.2967/jnumed.114.137166
Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer ima. Nucl Med Commun. 2016;37:1030–7.
pubmed: 27243215
doi: 10.1097/MNM.0000000000000547
Chan DLH, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, et al. Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics. 2017;7:1149–58.
pubmed: 28435454
pmcid: 5399582
doi: 10.7150/thno.18068
Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, et al. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE. Eur J Nucl Med Mol Imaging. 2017;44:490–9.
pubmed: 27704193
doi: 10.1007/s00259-016-3533-z
Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin cancer Res an Off J Am Assoc Cancer Res. 2010;16:978–85.
doi: 10.1158/1078-0432.CCR-09-1759
Skougaard K, Nielsen D, Jensen BV, Hendel HW. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab. J Nucl Med. 2013;54:1026–31.
pubmed: 23572497
doi: 10.2967/jnumed.112.111757
Ilan E, Sandström M, Wassberg C, Sundin A, Garske-Román U, Eriksson B, et al. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. J Nucl Med. 2015;56:177–82.
pubmed: 25593115
doi: 10.2967/jnumed.114.148437
Sabet A, Dautzenberg K, Haslerud T, Aouf A, Sabet A, Simon B, et al. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Eur J Nucl Med Mol Imaging. 2015;42:1238–46.
pubmed: 25808630
doi: 10.1007/s00259-015-3041-6
Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, et al. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. Eur J Nucl Med Mol Imaging. 2020;47:895–906.
pubmed: 31838581
doi: 10.1007/s00259-019-04601-3
Bodei L, Kidd M, Modlin IM, Severi S, Drozdov I, Nicolini S, et al. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2016;43:839–51.
pubmed: 26596723
doi: 10.1007/s00259-015-3250-z
Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, et al. PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy. Eur J Nucl Med Mol Imaging. 2018;45:1155–69.
pubmed: 29484451
pmcid: 6716527
doi: 10.1007/s00259-018-3967-6
Bodei L, Schöder H, Baum RP, Herrmann K, Strosberg J, Caplin M, et al. Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. Lancet Oncol. 2020;21:e431–43.
pubmed: 32888472
pmcid: 8385643
doi: 10.1016/S1470-2045(20)30323-5
Roll W, Riemann B, Schäfers M, Stegger L, Vrachimis A. 177Lu-DOTATATE therapy in radioiodine-refractory differentiated thyroid cancer: a single center experience. Clin Nucl Med. 2018;43:e346–51.
pubmed: 30059430
doi: 10.1097/RLU.0000000000002219
Werner RA, Solnes LB, Javadi MS, Weich A, Gorin MA, Pienta KJ, et al. SSTR-RADS version 1.0 as a reporting system for SSTR PET imaging and selection of potential PRRT candidates: a proposed standardization framework. J Nucl Med. 2018;59:1085–91.
pubmed: 29572257
doi: 10.2967/jnumed.117.206631
Werner RA, Derlin T, Rowe SP, Bundschuh L, Sheikh GT, Pomper MG, et al. High interobserver agreement for the standardized reporting system SSTR-RADS 1.0 on somatostatin receptor PET/CT. J Nucl Med. 2020;62:514–20.
Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, Hörsch D, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours [Internet]. Eur J Nucl Med Mol Imaging. 2013;40(5):800–16.
Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A, et al. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41:925–33.
pubmed: 24504504
doi: 10.1007/s00259-013-2677-3
Bodei L, Schöder H, Baum RP, Herrmann K, Strosberg J, Caplin M, et al. Review Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. Lancet Oncol. 2020;21:e431–43.
Paul P, Chakraborty A, Sarkar D, Langthasa M, Rahman M, Bari M, et al. Interplay between miRNAs and human diseases. J Cell Physiol. 2018;233:2007–18.
pubmed: 28181241
doi: 10.1002/jcp.25854
Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol Mech Dis. 2014;9:287–314.
doi: 10.1146/annurev-pathol-012513-104715
Di Leva G, Croce CM. MiRNA profiling of cancer. Curr Opin Genet Dev. 2013;23:3–11.
pubmed: 23465882
pmcid: 3632255
doi: 10.1016/j.gde.2013.01.004
Remon J, Caramella C, Jovelet C, Lacroix L, Lawson A, Smalley S, et al. Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:784–90.
doi: 10.1093/annonc/mdx017
Kidd M, Modlin I, Öberg K. Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms. Nat Rev Clin Oncol. 2016;13:691–705.
pubmed: 27273044
doi: 10.1038/nrclinonc.2016.85
Jiao Y, Shi C, Edil BH, De Wilde RF, Klimstra DS, Maitra A, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (80- ). 2011;331:1199–203.
doi: 10.1126/science.1200609
Shay JW, Reddel RR, Wright WE. Cancer: cancer and telomeres - an alternative to telomerase. Science (80- ). 2012;336:1388–90.
doi: 10.1126/science.1222394
Modlin IM, Drozdov I, Alaimo D, Callahan S, Teixiera N, Bodei L, et al. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection. Endocr Relat Cancer. 2014;21:615–28.
pubmed: 25015994
doi: 10.1530/ERC-14-0190
Modlin IM, Drozdov I, Kidd MS. A multitranscript blood neuroendocrine tumor molecular signature to identify treatment efficacy and disease progress. J Clin Oncol. 2013;31:4137.
Liu E, Paulson S, Gulati A, Freudman J, Grosh W, Kafer S, et al. Assessment of NETest clinical utility in a US registry-based study. Oncologist. 2019;24:783–90.
pubmed: 30158287
doi: 10.1634/theoncologist.2017-0623
Ćwikła JB, Bodei L, Kolasinska-Ćwikła A, Sankowski A, Modlin IM, Kidd M. Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy. J Clin Endocrinol Metab. 2015;100:E1437–45.
pubmed: 26348352
doi: 10.1210/jc.2015-2792
Pavel M, Jann H, Prasad V, Drozdov I, Modlin IM, Kidd M. NET blood transcript analysis defines the crossing of the clinical rubicon: when stable disease becomes progressive. Neuroendocrinology. 2017;104:170–82.
pubmed: 27078712
doi: 10.1159/000446025
Mayerhoefer ME, Prosch H, Beer L, Tamandl D, Beyer T, Hoeller C, et al. PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. Eur J Nucl Med Mol Imaging. 2020;47:51–60.
pubmed: 31410538
doi: 10.1007/s00259-019-04452-y
Wang H, Zhou Z, Li Y, Chen Z, Lu P, Wang W, et al. Comparison of machine learning methods for classifying mediastinal lymph node metastasis of non-small cell lung cancer from (18)F-FDG PET/CT images. EJNMMI Res. 2017;7:11.
pubmed: 28130689
pmcid: 5272853
doi: 10.1186/s13550-017-0260-9
Haubold J, Demircioglu A, Gratz M, Glas M, Wrede K, Sure U, et al. Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric (18)F-FET PET-MRI and MR fingerprinting. Eur J Nucl Med Mol Imaging. 2020;47:1435–45.
pubmed: 31811342
doi: 10.1007/s00259-019-04602-2
Xiang L, Qiao Y, Nie D, An L, Wang Q, Shen D. Deep auto-context convolutional neural networks for standard-dose PET image estimation from low-dose PET/MRI. Neurocomputing. 2017;267:406–16.
pubmed: 29217875
pmcid: 5714510
doi: 10.1016/j.neucom.2017.06.048
Liu F, Jang H, Kijowski R, Zhao G, Bradshaw T, McMillan AB. A deep learning approach for (18)F-FDG PET attenuation correction. EJNMMI Phys. 2018;5:24.
pubmed: 30417316
pmcid: 6230542
doi: 10.1186/s40658-018-0225-8
Weber WA, Gatsonis CA, Mozley PD, Hanna LG, Shields AF, Aberle DR, et al. Repeatability of 18F-FDG PET/CT in advanced non-small cell lung cancer: prospective assessment in 2 multicenter trials. J Nucl Med. 2015;56:1137–43.
pubmed: 25908829
doi: 10.2967/jnumed.114.147728
Makris NE, Huisman MC, Kinahan PE, Lammertsma AA, Boellaard R. Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures. Eur J Nucl Med Mol Imaging. 2013;40:1507–15.
pubmed: 23754762
pmcid: 6704482
doi: 10.1007/s00259-013-2465-0
Boellaard R, Oyen WJG, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35:2320–33.
pubmed: 18704407
doi: 10.1007/s00259-008-0874-2
Kwekkeboom DJ, De Herder WW, Kam BL, Van Eijck CH, Van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu- DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.
pubmed: 18445841
doi: 10.1200/JCO.2007.15.2553